Summary XpresSpa has pivoted its business from an airport spa business to an airport Covid testing business. XpresSpa has 99 cents a share in net balance sheet cash. It earned roughly 5 cents a share in the third quarter driven largely by Covid testing at airports. It is expanding this testing activity to additional airports and quarterly earnings should go up. A price of $4-5 per share is reasonable and would represent nearly a tripling of the current price.
XSPA has a solid balance sheet with $109.9 million in cash and $5.6 million in debt, netting out to 99 cents a share (share count is 105.3 million) in net balance sheet cash. With a share price of $1.77, this means that the market is valuing XSPA's business at 78 cents a share
These poor people Van. You see what they are paying? Europe is out, China rises. China makes friends with Russia. The door is wide open fro new Nukes. <--- In France this " type " of reactor i assume is not the nifty small type we have been looking at with Rolls Royce and ABB
This hit $57 today. For a minute we were up alot. VIR--------- GET IN! Vir Biotechnology, Inc. 54.032.41(+4.67%)4:00 PM 12/16/21 Post-Market:$54.05+0.02(+0.04%)7:38 PM
Oh totally! I thought you were talking about Xpress Spa<-- Love me some Covid testing at airports.... it's a must.